PURPOSE - To evaluate serial apparent diffusion coefficient (ADC) measurements of bone metastases in prostate cancer to determine whether antiandrogen resistance can be detected and time to progression estimated.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
MATERIALS AND METHODS - Diffusion-weighted imaging (DWI) was performed at 1. 5T in nine patients with treatment-naïve metastatic prostate cancer (20 lesions) before antiandrogen treatment, after 1, 2, and 3 months of treatment, and thereafter every 4 months over 31 months or until antiandrogen resistance was detected. Tumor volumes were stable over time. Time courses of the ADCs when averaged over entire lesions and on functional diffusion maps (fDMs) were analyzed using marginal linear model (MLM) analysis.
RESULTS - Starting at 1 month, MLM analysis revealed decreasing mean ADCs (P = 0. 001) over time. Simultaneously, the percentage of voxels with significantly higher ADCs decreased (P = 0. 004), whereas the percentage of voxels with significantly lower ADCs increased (P < 0. 001) on fDMs. Both mean ADCs (P = 0. 042) and percentages of voxels with significantly higher ADCs on fDMs (P = 0. 039) decreased more rapidly over time in patients with a shorter progression-free interval (PFI). Likewise, higher (P = 0. 001) and more rapidly increasing (P = 0. 002) percentages of voxels with significantly lower ADCs on fDMs were associated with a shorter PFI.
CONCLUSIONS - The results of our pilot study suggest that the evolution of ADCs over time may permit early identification of antiandrogen resistance in bone metastases. J. Magn. Reson. Imaging 2015.
Journal of magnetic resonance imaging : JMRI. 2015 Nov 20 [Epub ahead of print]
Carolin Reischauer, Dow-Mu Koh, Johannes M Froehlich, René Patzwahl, Christoph A Binkert, Andreas Gutzeit
Institute of Radiology and Nuclear Medicine, Clinical Research Unit, Hirslanden Hospital St. Anna, Lucerne, Switzerland. , Academic Department of Radiology, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. , Institute of Radiology and Nuclear Medicine, Clinical Research Unit, Hirslanden Hospital St. Anna, Lucerne, Switzerland. , Department of Radiology, Cantonal Hospital Winterthur, Winterthur, Switzerland. , Department of Radiology, Cantonal Hospital Winterthur, Winterthur, Switzerland. , Institute of Radiology and Nuclear Medicine, Clinical Research Unit, Hirslanden Hospital St. Anna, Lucerne, Switzerland.